Skip to main content

Sjögrens Disease

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
VAY736 1ml PFSPhase 21 trial
Active Trials
NCT06293365Active Not Recruiting155Est. Jan 2029
Kiniksa Pharmaceuticals
1 program
AbiprubartPHASE_21 trial
Active Trials
NCT06531395Terminated3Est. May 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
Kiniksa PharmaceuticalsAbiprubart
SandozVAY736 1ml PFS

Clinical Trials (2)

Total enrollment: 158 patients across 2 trials

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

Start: Jul 2024Est. completion: May 20253 patients
Phase 2Terminated
NCT06293365SandozVAY736 1ml PFS

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Start: Jul 2024Est. completion: Jan 2029155 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.